Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics


Milestone Pharmaceuticals Inc. (MIST): $6.07

-0.04 (-0.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MIST Stock Price Chart Interactive Chart >

Price chart for MIST

MIST Price/Volume Stats

Current price $6.07 52-week high $11.40
Prev. close $6.11 52-week low $3.18
Day low $5.91 Volume 14,398
Day high $6.14 Avg. volume 87,906
50-day MA $5.63 Dividend yield N/A
200-day MA $6.72 Market Cap 181.17M

Milestone Pharmaceuticals Inc. (MIST) Company Bio


Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.


MIST Latest News Stream


Event/Time News Detail
Loading, please wait...

MIST Latest Social Stream


Loading social stream, please wait...

View Full MIST Social Stream

Latest MIST News From Around the Web

Below are the latest news stories about Milestone Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIST as an investment opportunity.

Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET. The conference will be held in a virtual meeting format.

Yahoo | May 26, 2021

Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference - May 26, 2021

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET.

BioSpace | May 25, 2021

Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China

Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it’s touting new data on its secondary endpoints and a partnership with Ji Xing Pharmaceuticals to develop the candidate in China for paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions. Ji Xing is paying $15 million upfront and making a $5 million equity investment for the rights to develop and commercialize etripamil, a fast-acting calcium channel blocker, in Greater China. The agreement involves milestone payments of up to $107.5 million. At ACC 2021, Milestone said etripamil had higher scores than placebo related to relief of specific symptoms associated ...

Yahoo | May 17, 2021

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China.

BioSpace | May 16, 2021

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial

BioSpace | May 16, 2021

Read More 'MIST' Stories Here

MIST Price Returns

1-mo 11.38%
3-mo -13.90%
6-mo -11.52%
1-year 37.80%
3-year N/A
5-year N/A
YTD -9.40%
2020 -58.15%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7566 seconds.